Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study

Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study

Targeting L858R/T790M and L858R/T790M/C797S mutant EGFR is a critical challenge in developing EGFR tyrosine kinase inhibitors to overcome drug resistance in non-small cell lung cancer (NSCLC). The discovery of next-generation EGFR tyrosine kinase inhibitors (TKIs) is therefore necessary. To this end...

Full description

Bibliographic Details
Main Authors: Duangjai Todsaporn, Alexander Zubenko, Victor Kartsev, Thitinan Aiebchun, Panupong Mahalapbutr, Anthi Petrou, Athina Geronikaki, Liudmila Divaeva, Victoria Chekrisheva, Ilkay Yildiz, Kiattawee Choowongkomon, Thanyada Rungrotmongkol
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Molecules
Subjects:
furopyridine
molecular dynamics
drug screening
cytotoxicity
EGFR-TK
Online Access:https://www.mdpi.com/1420-3049/28/7/3014

Internet

https://www.mdpi.com/1420-3049/28/7/3014

Similar Items